Institutional investors purchased a net $23.7 thousand shares of STML during the quarter ended March 2016. This may signal that the smart money is gaining interest in this company as the 54.92% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
FRANKLIN ADVISERS, INC. Bought 126.7 Thousand shares of Stemline Therapeutics Inc
BAILARD, INC. Bought 94.8 Thousand shares of Stemline Therapeutics Inc